Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience

References

• Berges A. Schizophrenia In: Ferri FF, editor. Ferri’s Clinical Advisor 2021. Elsevier; 2021:1234.e6–1234.e8.
   Google Scholar
• Rice DP. The economic impact of schizophrenia. J Clin Psychiatry. 1999;60:4–6.
   PubMed Web of Science ®Google Scholar
• Mangalore R, Knapp M. Cost of schizophrenia in England. Ment Health Policy Econ. 2007;10:23–41.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Brown HE, Holt DJ, et al. Psychosis and Schizophrenia In: Stern TA, Fava M, Wilens TE, Rosenbaum JF, editors. Massachusetts General Hospital Comprehensive Clinical Psychiatry, 2nd NY: Elsevier; 2018:307–323.
   Google Scholar
• Andreasen NC, Arndt S, Alliger R, et al. Symptoms of Schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995;52(5):341–351. doi:10.1001/archpsyc.1995.039501700150037726714
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Goff DC, Henderson D. Antipychotic In: Stern TA, Fava M, Wilens TE, Rosenbaum JF, editors. Massachusetts General Hospital Comprehensive Clinical Psychiatry. 2nd ed. NY: Elsevier; 2018:475–488.
   Google Scholar
• Gilbert P, Harris MJ, McAdams LA. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52(3):173–188. doi:10.1001/archpsyc.1995.039501500050017872841
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46. doi:10.4088/JCP.7090su1cj19686636
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097. doi:10.1016/S0140-6736(08)60486-918374841
   PubMed Web of Science ®Google Scholar
• Grootens KP, van Veelen NM, Peuskens J, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37(2):352‐361. doi:10.1093/schbul/sbp037
   Web of Science ®Google Scholar
• Briles JJ, Rosenberg DR, Brooks BA, et al. Review of the safety of second-generation antipsychotics: are they really “atypically” safe for youth and adults? Prim Care Companion CNS Disord. 2012;14(3):PCC.11r01298. doi:10.4088/PCC.11r01298
   Google Scholar
• Kelly DL, Mcmahon RP, Liu F, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71(03):304–311. doi:10.4088/JCP.08m04718yel20079332
   PubMed Web of Science ®Google Scholar
• Bucci P, Galderisi S. Categorizing and assessing negative symptoms. Current Opin Psychiatry. 2017;30(3):201–208. doi:10.1097/YCO.0000000000000322
   PubMed Web of Science ®Google Scholar
• De Deurwaerdere P. Cariprazine: new dopamine biased agonist for neuropsychiatric disorders. Drugs Today (Barc). 2016;52(2):97–110. doi:10.1358/dot.2016.52.2.246186827092339
   PubMed Web of Science ®Google Scholar
• Wesołowska A, Partyka A, Jastrzebska-Wiesek M, et al. The preclinical discovery and development of cariprazine for the treatment of schizophrenia. Expert Opin Drug Discov. 2018;13(8):779–790. doi:10.1080/17460441.2018.147105729722587
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Reagila Assessment Report. 2017 Available from: https://www.ema.europa.eu/en/documents/assessment-report/reagila-epar-public-assessment-report_en.pdf.
   Google Scholar
• Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–340. doi:10.1124/jpet.109.16043220093397
   PubMed Web of Science ®Google Scholar
• Campbell RH, Diduch M, Gardner KN, et al. Review of cariprazine in management of psychiatric illness. Ment Health Clin. 2017;7(5):221–229. doi:10.9740/mhc.2017.09.22129955527
   PubMedGoogle Scholar
• Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113. doi:10.1016/S0140-6736(17)30060-028185672
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9. doi:10.1016/j.eurpsy.2019.01.01530738380
   PubMed Web of Science ®Google Scholar
• Corponi F, Serretti A, Montgomery S, et al. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017;32(6):309–318. doi:10.1097/YIC.000000000000018928727644
   PubMed Web of Science ®Google Scholar
• Roman V, Gyertyan I, Saghy K, et al. Cariprazine (RGH-188), a D 3-preferring dopamine D 3/D 2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. Psychopharmacology. 2013;226(2):285–293. doi:10.1007/s00213-012-2906-723138433
   PubMed Web of Science ®Google Scholar
• Drago F. The dopamine D3 receptor: from preclinical studies to the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(9):1399–1400. doi:10.1016/j.euroneuro.2015.07.02526278782
   PubMed Web of Science ®Google Scholar
• Pich EM, Collo G. Pharmacological targeting of dopamine D3 receptors: possible clinical applications of selective drugs. Eur Neuropsychopharmacol. 2015;25(9):1437–1447. doi:10.1016/j.euroneuro.2015.07.01226298833
   PubMed Web of Science ®Google Scholar
• Michino M, Boateng CA, Donthamsetti P, et al. Toward understanding the structural basis of partial agonism at the dopamine D3 receptor. J Med Chem. 2017;60(2):580–593. doi:10.1021/acs.jmedchem.6b0114827983845
   PubMed Web of Science ®Google Scholar
• Hernandez-Huerta D, Morillo-Gonzalez J. Dopamine D 3 partial agonists in the treatment of psychosis and substance use disorder comorbidity: a pharmacological alternative to consider? CNS Spectr. 2020;29:1–2. doi:10.1017/S1092852920001510
   Web of Science ®Google Scholar
• Earley W, Durgam S, Lu K, et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four Phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32(6):319–328. doi:10.1097/YIC.000000000000018728692485
   PubMed Web of Science ®Google Scholar